(NASDAQ: MGX) Metagenomi's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.47%.
Metagenomi's earnings in 2025 is -$77,949,000.On average, 5 Wall Street analysts forecast MGX's earnings for 2025 to be -$90,388,455, with the lowest MGX earnings forecast at -$115,882,635, and the highest MGX earnings forecast at -$53,829,353. On average, 4 Wall Street analysts forecast MGX's earnings for 2026 to be -$65,043,801, with the lowest MGX earnings forecast at -$106,537,261, and the highest MGX earnings forecast at -$24,297,972.
In 2027, MGX is forecast to generate -$106,537,261 in earnings, with the lowest earnings forecast at -$106,537,261 and the highest earnings forecast at -$106,537,261.